secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-104015
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome Q2 net loss $43.4M; cash $268M; varegacestat Phase 3 topline data by end 2025
--------------------------------------------------------------------------------

- Net loss of $43.4M for Q2 2025; cash, equivalents and securities $268M as of June 30.
- R&D expenses $40.5M, G&A $10.0M; cash expected to fund operations into 2027.
- Varegacestat Phase 3 RINGSIDE Part B topline data expected before end of 2025; EMA granted Orphan Drug Designation in July 2025.
- IM-1021 Phase 1 trial dosing at third dose level; IM-3050 IND cleared April 2025, Phase 1 start expected by end 2025.
- Three preclinical ADCs (IM-1617, IM-1340, IM-1335) undergoing IND-enabling work; additional undisclosed ADCs in discovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000095017025104015/0000950170-25-104015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000095017025104015/imnm-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer